Kyverna deprioritises next-generation autoimmune CAR-T programme as focus shifts to miv-cel
Kyverna Therapeutics has deprioritised its next-generation CAR-T candidate, KYV-102, as the company concentrates resources on advancing its lead programme, mivocabtagene autoleucel (miv-cel), towards potential commercialisation.
KYV-102 was an autologous CD19-targeting CAR-T therapy being developed for autoimmune diseases. Unlike conventional autologous CAR-T manufacturing, the candidate used Kyverna's whole-blood manufacturing process, designed to eliminate the need for apheresis and simplify treatment delivery. The approach was intended to broaden patient access, reduce manufacturing complexity and potentially lower treatment costs.
The programme had initially been expected to enter clinical development following FDA clearance in January 2026. However, in its latest third-quarter financial update, Kyverna confirmed that it had elected to deprioritise KYV-102, instead focusing on accelerating the development of miv-cel across its late-stage neurological autoimmune indications.
The decision comes as Kyverna approaches a significant regulatory milestone for miv-cel, completing its rolling Biologics License Application (BLA) submission to the FDA for the treatment of stiff person syndrome (SPS), requesting priority review. If approved, miv-cel would become the first CAR-T therapy approved for an autoimmune disease, with a potential US commercial launch in 2027.
Read more via Genome Web and Kyverna
Cellectis to cut up to 70% of workforce as company accelerates shift towards in vivo gene editing
French biotechnology company Cellectis is planning to reduce its global workforce by up to 70% as part of a major organisational restructuring designed to support its transition towards in vivo gene editing. The announcement follows the company's September decision to discontinue development of two clinical-stage allogeneic CAR-T candidates: lasme-cel, which was being investigated in a pivotal Phase 2 trial for B-cell acute lymphoblastic leukaemia (B-ALL), and eti-cel, which was in Phase 1 development for non-Hodgkin lymphoma (NHL).
Cellectis cited changes in the clinical and commercial landscape for both indications as key factors behind the decision, despite continued physician interest in allogeneic CAR-T approaches. The company subsequently redirected its resources towards two preclinical in vivo gene editing programmes: HEAL-101 and HEAL-201.
In its latest third-quarter financial update, Cellectis confirmed that its restructuring could result in a reduction of up to 70% of its workforce from pre-transition levels over 2026 and 2027, subject to the relevant employee consultation processes and regulatory requirements. The company entered 2026 with 229 full-time employees across its operations in France and the United States.
Cellectis' restructuring reflects a broader shift in industry investment towards in vivo approaches, as developers and pharmaceutical companies explore ways to overcome some of the manufacturing, scalability and logistical challenges associated with ex vivo cell therapies. Recent strategic investments and acquisitions by companies including AstraZeneca, AbbVie and Bristol Myers Squibb further illustrate the growing interest in this area.
Read more via Fierce Biotech and Cellectis
Sofinnova Partners closes €725 million fund to support European biotech growth
European life sciences investment firm Sofinnova Partners has closed its second crossover fund at €725 million, exceeding its original fundraising target and reinforcing investor appetite for later-stage biotechnology and medical technology companies.
The new vehicle, Sofinnova Crossover II, will primarily invest in European clinical-stage biopharmaceutical and medtech businesses seeking capital to progress towards commercialisation and international expansion. The fund will also consider selected opportunities in the United States and other global markets.
Sofinnova expects to support approximately 15 high-growth companies through the fund, providing capital to businesses navigating the transition from clinical development to commercial scale. The strategy is designed to address a recognised funding gap within the European life sciences ecosystem, where companies can demonstrate strong scientific and clinical progress but often face challenges securing the substantial investment required to compete globally.
The fund has already backed three companies: Hemab Therapeutics, CellCentric, and Neurent Medical. The fundraising comes at a time when access to growth capital remains a significant consideration for European biotech companies. While early-stage scientific innovation continues to emerge across the region, securing the funding required to advance clinical programmes, prepare for regulatory approval and establish commercial operations remains a challenge.
Read more via BioPharma Dive and Sofinnova Partners